Orion Defends Position In Declining Finnish Market
Norwegian Tender Win Boosts Biosimilars Sales
Amid declining sales of drugs covered by reference prices in Finland, local leader Orion says it has been able to slightly strengthen its market position.
You may also be interested in...
A sluggish start to selling its salmeterol/fluticasone device in Europe did not prevent Finland’s Orion from growing its Easyhaler line of respiratory devices in the first half of 2019.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.